Slides
Page 1
20 26 CHIMERIC THERA PEUTIC S CHIM ERI CTHERAP EUT ICS. COM CHIMERIC PIONEERS IN CELL THERAPY CHM A SX :
Page 2
CHIMERIC THERA PEUTIC S CHIM ERI CTHERAP EUT ICS. COM Certain statements contained in this presentation, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Chimeric (collectively, “Chimeric” or the “Company”) to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law. This presentation may not contain all the details and information necessary for you to make a decision or evaluation. Neither this presentation nor any of its contents may be used for any other purpose without the prior written consent of the Company. DISCLAIMER 2
Page 3
CHIMERIC THERA PEUTIC S CHIM ERI CTHERAP EUT ICS. COM 3 0 Exchange Share Price 52 Week Range Market Cap Shares on issue IPO 2021 ASX: CHM $0.036 $0.036 – 0.40 ~59m CORPORATE PROFILE INVESTMENT OVERVIEW 3 3 Phase 1 clinical trials Multiple clinical updates Experienced leadership team the FIRST CDH17 CAR-T in clinical trials Robust and long life ~ 3.1m
Page 4
CHIMERIC THERA PEUTIC S CHIM ERI CTHERAP EUT ICS. COM 4 2 Novel cell therapies; 3 Clinical Trials CHM CDH17 CAR-T CHM CORE-NK ‘OFF THE SHELF’ NK PHASE 1/2 TRIAL OPEN 4 sites active PHASE 1B TRIAL OPEN PHASE 1B TRIAL SUSPENDED MD Anderson Case Western CHM: FOCUSED PORTFOLIO
Page 5
20 26 CHIMERIC THERA PEUTIC S CHIM ERI CTHERAP EUT ICS. COM CHM CDH17 CHM A SX :
Page 6
CHIMERIC THERA PEUTIC S CHIM ERI CTHERAP EUT ICS. COM 6 CDH17 CAR T induced complete eradication of tumours with no relapse in seven mouse models ENCOURAGING PRE-CLINICAL RESULTS PANCREATIC CANCER NEUROENDOCRINE TUMOURS GASTRIC CANCER CHM CDH17 CAR-T Source:Feng et al., Nature Cancer, 2022
Page 7
CHIMERIC THERA PEUTIC S CHIM ERI CTHERAP EUT ICS. COM 7 The first CDH17 CAR T cell therapy in clinical trials globally CHM CDH17 CAR-T PHASE 1/2 TRIAL OPEN 4 sites actively recruiting PERSONALISED CAR-T: AUTOLOGOUS 4 sites actively recruiting: Sarah Cannon, UPenn, UChicago, Emory FDA IND November 2023 First Patient Dosed August 2024 FASTRACK Designation April 2025: Neuroendocrine Tumours ORPHAN Designation December 2025: Gastric Cancer Manufacturing: 15/15 successful runs; GMP Compliant 16 Patients enrolled: 14 Patients treated, 1 awaiting dosing N= up to 15 evaluable patients CHM CDH17 CAR-T PHASE 1 RECRUITING NCT06055439
Page 8
CHIMERIC THERA PEUTIC S CHIM ERI CTHERAP EUT ICS. COM Phase 1/2 Clinical Trial of CHM CDH17 OPEN COMPLETE COMPLETE OPEN NCT06055439
Page 9
CHIMERIC THERA PEUTIC S CHIM ERI CTHERAP EUT ICS. COM 9 CHM CDH17 PROGRESS AS AT JULY 21, 2026 NCT06055439
Page 10
CHIMERIC THERA PEUTIC S CHIM ERI CTHERAP EUT ICS. COM CHM CDH17 PROGRESS AS AT JULY 21, 2026 BEFORE Treatment AFTER Treatment Images shared with consent DL2 150million cells
Page 11
CHIMERIC THERA PEUTIC S CHIM ERI CTHERAP EUT ICS. COM 11 TOTAL GLOBAL MARKET SIZE 27.7B in 2024
Page 12
CHIMERIC THERA PEUTIC S CHIM ERI CTHERAP EUT ICS. COM CHM CDH17 CHM CDH17 CHM 2101 14 patients treated, 1 awaiting treatment 15/15 manufacturing runs Anti-tumour activity observed No safety issues to date No off-target effects Complete Dose level 2 Commence Dose level 3 Conclude Phase 1 Phase 2 readiness
Page 13
20 26 CHIMERIC THERA PEUTIC S CHIM ERI CTHERAP EUT ICS. COM CHM CORE NK CHM A SX :
Page 14
CHIMERIC THERA PEUTIC S CHIM ERI CTHERAP EUT ICS. COM 14 Phase 1b clinical trials OPEN OFF THE SHELF: ALLOGENEIC NK cell expansion platform: Universal Donor Positive Phase 1A Clinical Trial in AML Two ongoing Phase 1B Clinical Trials in AML MDACC AML: Cohort 1 cleared, moved to dose expansion for Cohort 2 FRONTLINE - A FIRST IN CELL THERAPY Multiple Patient dosed; rapidly recruiting Case Western AML: Trial suspended due to IL -2 Shortage CHM CORE-NK 2 PHASE 1B TRIALS OPEN CHM CORE-NK ‘OFF THE SHELF’ NK PHASE 1B TRIAL OPEN PHASE 1B TRIAL OPEN MD Anderson Case Western PHASE 1B TRIAL OPEN PHASE 1B TRIAL SUSPENDED
Page 15
CHIMERIC THERA PEUTIC S CHIM ERI CTHERAP EUT ICS. COM 15 CHM CORE-NK + AZA + VEN in FRONTLINE AML Clinical Trials.gov Identifier: NCT05834244 AML PHASE 1B CLINICAL TRIAL OPEN CORE NK CELLS FDA REGISTERED CHEMOTHERAPY FDA REGISTERED BLOOD CANCER DRUG CHM CORE NK ‘OFF THE SHELF’ NK
Page 16
CHIMERIC THERA PEUTIC S CHIM ERI CTHERAP EUT ICS. COM 16 CHM CORE-NK FRONTLINE PHASE 1 STUDY RESULTS FrontLine Patients with no prior treatment 15/25 Complete responses Complete Response means that all visible or measurable signs of cancer have disappeared after treatment First line Dosing Underway
Page 17
CHIMERIC THERA PEUTIC S CHIM ERI CTHERAP EUT ICS. COM 17 CHM CORE-NK CHM CDH17 CHM 2101 Investigator Sponsored Trial – MD ANDERSON Dose Escalation completed First Line Dosing Underway – up to 20 patients No safety issues to date Complete dosing of 20 patients; subject to MD Anderson CHM CORE-NK ‘OFF THE SHELF’ NK
Page 18
CHIMERIC THERA PEUTIC S CHIM ERI CTHERAP EUT ICS. COM 10 SUMMARY CHM CORE-NK ‘OFF THE SHELF’ NK CHM CDH17 CHM 2101 14 patients treated 15/15 manufacturing runs Tumour shrinkage observed No unexpected safety issues to date No off-target effects Investigator Sponsored Trial – MD ANDERSON Dose Escalation completed First Line Dosing Underway No safety issues to date
Page 19
20 26 CHIMERIC THERA PEUTIC S CHIM ERI CTHERAP EUT ICS. COM CHIMERIC PIONEERS IN CELL THERAPY investors@chimerictherapeutics.com CHM A SX :